Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells

[1] Takeshita Y(2012)Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models Immunol Rev 248 228-239

[2] Ransohoff RM(2006)A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 899-910

[3] Polman CH(2014)Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study Neurology 83 78-86

[4] O'Connor PW(2017)Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies Lancet Neurol 16 925-933

[5] Havrdova E(2019)Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis Ther Adv Neurol Disord 12 1756286419837809-1930

[6] Hutchinson M(2016)Disrupted balance of T cells under natalizumab treatment in multiple sclerosis Neurol (R) Neuroimmunol Neuroinflamm 3 1922-50

[7] Kappos L(2009)Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells Neurology 72 47-43

[8] Miller DH(2017)CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients J Neuroimmunol 309 31-3427

[9] O'Connor P(2016)Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis Ther Adv Neurol Disord 9 802-632

[10] Goodman A(2014)Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis J Immunol Res 2014 3411-815

[1] Takeshita Y(2012)Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models Immunol Rev 248 228-239

[2] Ransohoff RM(2006)A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 899-910

[3] Polman CH(2014)Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study Neurology 83 78-86

[4] O'Connor PW(2017)Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies Lancet Neurol 16 925-933

[5] Havrdova E(2019)Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis Ther Adv Neurol Disord 12 1756286419837809-1930

[6] Hutchinson M(2016)Disrupted balance of T cells under natalizumab treatment in multiple sclerosis Neurol (R) Neuroimmunol Neuroinflamm 3 1922-50

[7] Kappos L(2009)Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells Neurology 72 47-43

[8] Miller DH(2017)CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients J Neuroimmunol 309 31-3427

[9] O'Connor P(2016)Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis Ther Adv Neurol Disord 9 802-632

[10] Goodman A(2014)Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis J Immunol Res 2014 3411-815